Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Launches New Immunoassay Kits

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Ready-to-use kits are fully qualified for reliable use in clinical research.

Merck Millipore has announced the release of five new immunoassay kits designed specifically for use on the Gyrolab™ workstation.

The new, fully qualified GyroMark™ HT kits from Merck Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.

Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, approximately 500 samples can be analyzed within four hours.

"Our collaboration with Gyros will fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform," says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at Merck Millipore.

The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1. Merck Millipore plans to release additional kits this year, and is offering custom kits for companies with specific needs or unique or novel antibodies.

Because the Gyrolab™ platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings.

GyroMark™ HT assays provide accuracy over a four-log dynamic range (compared to two logs for ELISAs), elimination of cross-talk and plate position artifacts, and simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference.

Gyros' Global Marketing Director Maria Hjortsmark commented: "The Gyrolab™ platform revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that Merck Millipore has chosen to work with us to develop off-the-shelf kits, to further reduce time to results that will free up analyst time, and offering an easier route to robust, reproducible data."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Announces New Genomic Biomarker Services
Genetic and epigenetic technologies added to established CRO services for biomarker development, validation and testing.
Wednesday, December 05, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos